Fox Jonathan C 4

What Happened
Jonathan C. Fox, a director of Edgewise Therapeutics, was granted and had 319 restricted stock units (RSUs) released to him on July 1, 2026 as a Quarterly Retainer Award. The Form 4 reports the acquisition as 319 shares at $0.00 (transaction code A — award/grant).

Key Details

• Transaction date: 2026-07-01; transaction type: Award/Acquisition (A).
• Price reported on Form 4: $0.00; total reported acquisition value: $0 (this reflects the award nature on the form).
• Shares owned after the transaction: not specified in the provided filing.
• Footnote: "Consists of restricted stock units granted and released to the reporting person on July 1, 2026, as a Quarterly Retainer Award pursuant to Section 2.4 of the Edgewise Therapeutics, Inc. Outside Directors Compensation Policy, as amended."
• Timeliness: Period of report and filing date are 2026-07-01 — appears to be filed timely (no late filing indicated).

Context
This was a compensation-related award to an outside director (routine retainer pay), not an open-market purchase or sale. Such RSU releases are common for board compensation and do not, by themselves, indicate the director is buying or selling shares for investment reasons.